A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Neoplasms
  • Thalidomide

abstract

  • The combination of thalidomide and cyclophosphamide as described herein has a modest and tolerable toxicity profile but little evidence of efficacy.

publication date

  • September 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/pbc.21045

PubMed ID

  • 16972243

Additional Document Info

start page

  • 261

end page

  • 5

volume

  • 49

number

  • 3